CDXS
Codexis, Inc. Healthcare - Biotechnology Investor Relations →
Codexis, Inc. (CDXS) closed at $1.60 as of 2026-03-20, trading 56.6% below its 200-week moving average of $3.69. This places CDXS in the extreme value zone. The stock moved further from the line this week, up from -56.9% last week. The 14-week RSI sits at 48, indicating neutral momentum.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (2.15 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 782 weeks of data, CDXS has crossed below its 200-week moving average 7 times. On average, these episodes lasted 60 weeks. Historically, investors who bought CDXS at the start of these episodes saw an average one-year return of +25.3%.
With a market cap of $145 million, CDXS is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -74.9%. The stock trades at 2.9x book value.
Share count has increased 37.5% over three years, indicating dilution.
Over the past 15.1 years, a hypothetical investment of $100 in CDXS would have grown to $13, compared to $641 for the S&P 500. CDXS has returned -12.6% annualized vs 13.1% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 11 open-market purchases totaling $7,753,042. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while CDXS is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CDXS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CDXS Crosses Below the Line?
Across 7 historical episodes, buying CDXS when it crossed below its 200-week moving average produced an average return of +10.4% after 12 months (median -62.0%), compared to +18.3% for the S&P 500 over the same periods. 43% of those episodes were profitable after one year. After 24 months, the average return was -34.6% vs +30.7% for the index.
Each line shows $100 invested at the moment CDXS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CDXS has crossed below its 200-week MA 7 times with an average 1-year return of +25.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2011 | May 2011 | 3 | 6.0% | -64.2% | -83.3% |
| Jun 2011 | Jan 2015 | 188 | 77.4% | -61.1% | -83.2% |
| Mar 2020 | May 2020 | 11 | 19.3% | +114.5% | -83.7% |
| Jun 2020 | Jul 2020 | 7 | 8.7% | +104.3% | -85.1% |
| Sep 2020 | Oct 2020 | 4 | 5.3% | +135.4% | -86.0% |
| Mar 2022 | Mar 2022 | 1 | 1.7% | -77.3% | -91.2% |
| Apr 2022 | Ongoing | 206+ | 89.1% | Ongoing | -91.3% |
| Average | 60 | — | +25.3% | — |
Frequently Asked Questions
Is CDXS below its 200-week moving average?
Yes. As of 2026-03-20, Codexis, Inc. (CDXS) is trading 56.6% below its 200-week moving average of $3.69. The current price is $1.60.
What is CDXS's 200-week moving average price?
Codexis, Inc.'s 200-week moving average is $3.69 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CDXS drops below its 200-week moving average?
CDXS has crossed below its 200-week moving average 7 times in our data. On average, buying at that moment produced a one-year return of +25.3%. These dips have historically been decent entry points. These episodes lasted 60 weeks on average.
Is CDXS a good value right now?
Here's what our data says about CDXS as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 48. Free cash flow is currently negative. Return on equity is -74.9%. Price-to-book is 2.9x. This is not a buy or sell recommendation — always do your own research.
How does CDXS compare to the S&P 500?
Over the past 15.1 years, $100 invested in CDXS would have grown to $13, compared to $641 for the S&P 500. That's -12.6% annualized vs 13.1% for the index. CDXS has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20